Medical Technology Breaking News:
Aethlon Medical (OTC: AEMDD) Announces Cancer Clinical Trial Agreement
SAN DIEGO - April 15, 2015
(Investorideas.com newswire) Aethlon Medical, Inc. (OTC:AEMDD),
a pioneer in developing targeted therapeutic devices to address infectious
diseases and cancer, announced today that it has entered into an
investigator-initiated clinical trial agreement with the University of
California, Irvine (UCI). Under the agreement, a clinical study protocol
entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing
Treatment," will seek to enroll five individuals in each of nine defined
tumor types for a total study population of up to 45 subjects. The tumor types
include the following forms of cancer; Breast adenocarcinoma, Colorectal,
Gastric & Gastroesophageal, Pancreatic, Cholangiocarcinoma, Lung (NSCLC),
Head & Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal
investigator of the study is Edward Nelson, M.D.
The study endpoints include establishing baseline
exosome levels and monitoring changes in circulating exosome concentration
associated with tumor treatment and the association of longitudinal changes in
circulating exosome concentrations with response to treatment.
The clinical study will also provide data to help
direct future clinical investigations of the Aethlon Hemopurifier® as a
therapeutic candidate to reduce the presence of circulating tumor-derived
exosomes, which are known to suppress the immune system of cancer patients and
contribute to the spread of metastasis. Aethlon Medical believes that the
Hemopurifier is a first-in-class bio-filtration device that targets the
single-use removal of viruses and tumor-derived exosomes from the circulatory
system.
Recruitment of participants in the study will be
through the use of internal and outside referrals to the University of
California, Irvine Medical Center (UCIMC). Review and approval of this human
protocol will be conducted by the UCI Institutional Review Board (IRB) Human
Subjects Review Committee.
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease and cancer. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively targets the rapid
elimination of circulating viruses and tumor-secreted exosomes that promote
cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that
is advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. Additional information can be found on-line
at http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that Exosome Sciences, Inc. will not be able to
commercialize its future products, including any that can be described as a
liquid biopsy, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA contract,
product liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including the
risks associated with the effect of changing economic conditions and other risk
factors detailed in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
No comments:
Post a Comment